Drug Design, Development and Therapy (Dec 2024)
Unveiling the Mechanisms and Therapeutic Effects of Xiaoyao Sanjie Decoction in Triple-Negative Breast Cancer: A Network Pharmacology and Experimental Validation Approach
Abstract
Yu Qi,1,* Bo Xu,2,3,* Jinrong He,4,* Bo Jiang,1 Le Yan,1 Haiyan Zhou,5 Saili Chen6– 9 1Traditional Chinese Medicine Classics Laboratory, Hubei University of Chinese Medicine, Wuhan, People’s Republic of China; 2Postdoctoral Mobile Workstation, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 3Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 4Key Laboratory for Molecular Diagnosis of Hubei Province, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 5Foreign Languages College, Hubei University of Science and Technology, Xianning, People’s Republic of China; 6Clinical Medical College, Hubei University of Science and Technology, Xianning, People’s Republic of China; 7National Demonstration Center for Experimental (General Practice) Education (Hubei University of Science and Technology), Xianning, People’s Republic of China; 8Xianning Heji Hospital of Integrated Chinese and Western Medicine, Xianning, People’s Republic of China; 9Xianning Traditional Chinese Medicine Chronic Disease Conditioning and Cancer Rehabilitation Joint Innovation Center, Xianning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Saili Chen, Clinical Medical College, Hubei University of Science and Technology, Xianning, People’s Republic of China, Email [email protected]: Triple-negative breast cancer (TNBC) is a disease associated with high incidence and high mortality, which is a major problem threatening women’s health. Xiaoyao Sanjie Decoction (XYSJD) exhibits remarkable therapeutic efficacy on TNBC; however, the underlying mechanism is unclear. This study verified the efficacy of XYSJD and its active component in the treatment of TNBC and explored its potential mechanism.Methods: Ultra-high performance liquid chromatography-hybrid quadrupole orbitrap mass spectrometry (UHPLC-Q Exactive HFX-MS) was applied to explore the main chemical constituents of XYSJD. The key targets and potential mechanisms of XYSJD in the treatment of TNBC were predicted through network pharmacology, bioinformatics analysis and molecular docking. The effects of XYSJD against TNBC cells were evaluated by CCK-8 assay, EdU assay, wound healing assay, transwell assay, Hoechst-PI staining and flow cytometry. The mechanism of action was validated by Western blot analysis. Finally, the effect and mechanism of XYSJD and Que on TNBC were further verified by the tumor formation model.Results: UHPLC-Q Exactive HFX-MS identified a total of 9 compounds in XYSJD. Network pharmacological methods identified 206 targets for anti-TNBC. Bioinformatics analysis suggests that the EZH2/AKT1 signaling pathway might play an important role in the effects of XYSJD against TNBC. Gene Ontology enrichment analysis showed that the biological process of XYSJD in TNBC treatment mainly involved apoptosis. XYSJD and Que were observed to have a good anticancer effect in vivo and in vitro. In addition, quercetin could induce the apoptosis of TNBC cells by decreased the expression levels of EZH2/AKT1 signaling pathway. Furthermore, AKT1 overexpression, treatment with the AKT activator (SC79) and EZH2 overexpression could reverse apoptosis induced by quercetin in TNBC cells.Conclusion: This study revealed the anti-TNBC efficacy of XYSJD. Quercetin, the effective component of XYSJD, promoted apoptosis of TNBC cells via blockade of the EZH2/AKT1 signaling pathway. These findings aim to provide a more reliable basis for the clinical application of XYSJD in the treatment of TNBC.Keywords: Xiaoyao Sanjie Decoction, triple-negative breast cancer, network pharmacology, quercetin, EZH2/AKT1 signaling pathway
